Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

25 results
Display

Comparative Analysis of Treatment Outcomes Following Regular vs. Irregular Administration of Biologics in Patients with Psoriasis

Choi GW, Lim NJ, Shin JU, Lee HJ, Yoon MS, Kim DH

  • KMID: 2518986
  • Korean J Dermatol.
  • 2021 Jul;59(6):440-446.
Background: Patients with stable psoriasis showing clear/near-clear response can consider extending the dosing interval of biologics. However, few studies have reported the treatment outcomes following irregular dosing intervals of biologics...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Biologic therapies for the treatment of psoriatic arthritis

Kim TJ

Psoriatic arthritis (PsA) is a chronic inflammatory rheumatic disease commonly associated with plaque psoriasis that, manifests with peripheral arthritis, dactylitis, enthesitis, and axial involvement. PsA can be progressive and harmful,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Biologic therapies for the treatment of ankylosing spondylitis

Ahn SM, Kim YG

Ankylosing spondylitis (AS) is a chronic inflammatory disease predominantly affecting the axial skeleton. AS treatment aims to reduce pain and inflammation and maintain functional capacity. Nonsteroidal anti-inflammatory drugs are the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Biologic therapies for the treatment of systemic lupus erythematosus

Park SH

Systemic lupus erythematosus is a typical autoimmune disease with a complex etiology, including the interaction of genetic/epigenetic factors and environmental and hormonal factors with innate immune cells or B/T lymphocytes....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Biologic therapies for the treatment of rheumatoid arthritis

Choi SJ

Rheumatoid arthritis (RA) is a chronic autoimmune disease that primarily affects the synovial joints. If left untreated, persistent synovial inflammation can lead to cartilage and bone destruction, ultimately causing significant...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Advantages and disadvantages of targeted therapy in patients with rheumatoid arthritis

Sung YK

With the recent understanding of the pathogenesis of rheumatoid arthritis at the cellular and molecular levels, as well as the rapid progress of biotechnology, targeted therapies have been developed and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Disseminated Tuberculosis in a Psoriasis Patient under Adalimumab Treatment despite the Chemoprophylaxis of Latent Tuberculosis: A Case Report

Oh JH, Ham SP, Park HJ

Recently, biologic therapy has become a major advance in the management of moderate-to-severe psoriasis. Although the overall safety profile of biologics is favorable, primary infection or reactivation of latent tuberculosis...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Sec-O-glucosylhamaudol mitigates inflammatory processes and autophagy via p38/JNK MAPK signaling in a rat neuropathic pain model

Oh SH, Kim SW, Kim DJ, Kim SH, Lim KJ, Lee K, Jung KT

Background: This study investigated the effect of intrathecal Sec-O-glucosylhamaudol (SOG) on the p38/c-Jun N-terminal kinase (JNK) signaling pathways, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)-related inflammatory responses, and autophagy...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
KOBIO, the First Web-based Korean Biologics Registry Operated With a Unified Platform Among Distinct Disease Entities

Kim J, Koh JH, Choi SJ, Jeon CH, Kwok SK, Kim SK, Choi CB, Lee J, Lee C, Nam EJ, Park YB, Lee SS, Kim TH, Park SH, Choe JY, Koh EM, Yoo DH, Song YW, Kim HA, Shin K

The KOrean College of Rheumatology BIOlogics and targeted therapy (KOBIO) registry is a nationwide observational cohort that captures detailed data on exposure of patients to biologic and targeted synthetic disease-modifying...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Biological treatments for severe asthma

Jin HJ

Severe asthma patients comprise about 3% to 13% of all asthma patients, but they have higher hospital utilization rates and higher medical costs than those of nonsevere asthma patients. Treatment...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Critical Points on the Use of Biologicals in Allergic Diseases and Asthma

Agache I, Cojanu C, Laculiceanu A, Rogozea L

Improved understanding of the contribution of immune-inflammatory mechanisms in allergic diseases and asthma has encouraged development of biologicals and small molecules specifically targeting the innate and adaptive immune response. There...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of Treatment Guidelines for Ulcerative Colitis: Role of Biologics

Bae JH, Yang DH

Ulcerative colitis (UC) is a chronic inflammatory condition of the colon, characterized by diffuse mucosal inflammation with bloody diarrhea. The therapeutic goals in UC have evolved from symptomatic relief to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Paradoxical Flare of Pustular Psoriasis after Ustekinumab Therapy

Kang IH, Shin MK, Lee MH, Jeong KH

  • KMID: 2436996
  • Korean J Dermatol.
  • 2018 Nov;56(9):548-551.
Biologics are the most advanced treatment for psoriasis. Ustekinumab, one of the biologics for psoriasis, is a human monoclonal antibody that binds to the p40 subunit of interleukin-12 and interleukin-23....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Reversal of Immunogenicity in Pediatric Inflammatory Bowel Disease Patients Receiving Anti-Tumor Necrosis Factor Medications

Kang E, Khalili A, Splawski J, Sferra TJ, Moses J

Loss of response to anti-tumor necrosis factor (anti-TNF) agents in the treatment of inflammatory bowel disease (IBD) is a major consideration to maintain sustained response. Reversal of immunogenicity can re-establish...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Add-on Therapy for Symptomatic Asthma despite Long-Acting Beta-Agonists/Inhaled Corticosteroid

Dreher M, Müller T

Asthma, remains symptomatic despite ongoing treatment with high doses of inhaled corticosteroids (ICS) in conjunction with long-acting beta-agonists (LABA), is classified as “severe” asthma. In the course of caring for...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Updated treatment strategies for intestinal Behçet's disease

Park YE, Cheon JH

Behçet's disease (BD) is a chronic, idiopathic, relapsing immune-mediated disease involving multiple organs, and is characterized by recurrent oral and genital ulcers, ocular disease, gastrointestinal ulcers, vascular diseases, and skin...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial

Inoue N, Kobayashi , Naganuma M, Hirai F, Ozawa M, Arikan D, Huang B, Robinson A, Thakkar RB, Hibi T

BACKGROUND/AIMS: Intestinal Behçet's disease (BD) is an immune-mediated inflammatory disorder. We followed up the patients and evaluated safety profile and effectiveness of adalimumab for the treatment of intestinal BD through...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparative efficacy of biological agents in methotrexate-refractory rheumatoid arthritis patients: a Bayesian mixed treatment comparison

Choi M, Hyun MK, Choi S, Tchoe HJ, Lee SY, Son KM, Kim MJ, Jung YO, Kim HA

BACKGROUND/AIMS: Biological agents (biologics) targeting proinflammatory signaling have emerged as an important treatment option in rheumatoid arthritis (RA). Despite the clinical effectiveness of biologics for patients with RA who do...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Biologics for the treatment of pyoderma gangrenosum in ulcerative colitis

Arivarasan K, Bhardwaj V, Sud S, Sachdeva S, Puri AS

Pyoderma gangrenosum (PG) is an uncommon extra-intestinal manifestation of inflammatory bowel disease (IBD). Despite limited published literature, biologics have caused a paradigm shift in the management of this difficult-to-treat skin...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Erythrodermic Psoriasis Treated with Golimumab: A Case Report

Lee WK, Kim GW, Cho HH, Kim WJ, Mun JH, Song M, Kim HS, Ko HC, Kim MB, Kim BS

Erythrodermic psoriasis (EP) is a very severe variant of psoriasis whose management poses a challenge to physicians, as currently available therapies often provide unsatisfactory results. Many biologics have been used...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr